Biological efficacy of twice daily aspirin in type 2 diabetic patients with coronary artery disease

American Heart Journal

Volumn 164, Issue 4, 2012, Pages

  Dillinger, Jean Guillaume ^a   Drissa, Akram ^a   Sideris, Georgios ^a   Bal Dit Sollier, Claire ^a   Voicu, Sebastian ^a   Manzo Silberman, Stephane ^a   Logeart, Damien ^a   Drouet, Ludovic ^a   Henry, Patrick ^a  

^a HÔPITAL LARIBOISIÈRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; ARACHIDONIC ACID; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; FIBRINOGEN; INSULIN; PROTON PUMP INHIBITOR;

ADULT; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CROSSOVER PROCEDURE; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SMOKING; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; TREATMENT OUTCOME;

EID: 84867562008     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2012.06.008     Document Type: Article

References (39)

1. G. Roglic, N. Unwin, and P.H. Bennett The burden of mortality attributable to diabetes: realistic estimates for the year 2000 Diabetes Care 28 2005 2130 2135
2. M.A. Creager, T.F. Luscher, and F. Cosentino Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I Circulation 108 2003 1527 1532
3. American Diabetes Association Standards of medical care in diabetes - 2010 Diabetes Care 33 Suppl. 1 2010 S11 S61
4. L. Ryden, E. Standl, and M. Bartnik Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD) Eur Heart J 28 2007 88 136
5. Antithrombotic Trialists' Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients BMJ 324 2002 71 86
6. J. Belch, A. MacCuish, and I. Campbell The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease BMJ 337 2008 a1840
7. S.D. Wiviott, E. Braunwald, and D.J. Angiolillo Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel - Thrombolysis in Myocardial Infarction 38 Circulation 118 2008 1626 1636
8. S.R. Mehta, J.F. Tanguay, and J.W. Eikelboom Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial Lancet 376 2010 1233 1243
9. P. Henry, A. Vermillet, and B. Boval 24-hour time-dependent aspirin efficacy in patients with stable coronary artery disease Thromb Haemost 105 2011 336 344
10. G. Montalescot, G. Sideris, and C. Meuleman A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial J Am Coll Cardiol 48 2006 931 938
11. P.A. Gum, K. Kottke-Marchant, and P.A. Welsh A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease J Am Coll Cardiol 41 2003 961 965
12. D.J. Angiolillo, A. Fernandez-Ortiz, and E. Bernardo Influence of aspirin resistance on platelet function profiles in patients on long-term aspirin and clopidogrel after percutaneous coronary intervention Am J Cardiol 97 2006 38 43
13. P.A. Gum, K. Kottke-Marchant, and E.D. Poggio Profile and prevalence of aspirin resistance in patients with cardiovascular disease Am J Cardiol 88 2001 230 235
14. D. Capodanno, A. Patel, and K. Dharmashankar Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with coronary artery disease Circ Cardiovasc Interv 4 2011 180 187
15. G. Spectre, L. Arnetz, and C.G. Ostenson Twice daily dosing of aspirin improves platelet inhibition in whole blood in patients with type 2 diabetes mellitus and micro- or macrovascular complications Thromb Haemost 106 2011 491 499
16. G.J. Hankey, and J.W. Eikelboom Aspirin resistance Lancet 367 2006 606 617
17. G. Krasopoulos, S.J. Brister, and W.S. Beattie Aspirin resistance and risk of cardiovascular morbidity: systematic review and meta-analysis BMJ 336 2008 195 198
18. P.J. Mason, A.K. Jacobs, and J.E. Freedman Aspirin resistance and atherothrombotic disease J Am Coll Cardiol 46 2005 986 993
19. S.A. McKee, D.C. Sane, and E.N. Deliargyris Aspirin resistance in cardiovascular disease: a review of prevalence, mechanisms, and clinical significance Thromb Haemost 88 2002 711 715
20. K.H. Grotemeyer, H.W. Scharafinski, and I.W. Husstedt Two-year follow-up of aspirin responder and aspirin non responder. A pilot-study including 180 post-stroke patients Thromb Res 71 1993 397 403
21. K.A. Schwartz, D.E. Schwartz, and K. Barber Non-compliance is the predominant cause of aspirin resistance in chronic coronary arterial disease patients J Transl Med 6 2008 46
22. M. Wurtz, E.L. Grove, and S.D. Kristensen The antiplatelet effect of aspirin is reduced by proton pump inhibitors in patients with coronary artery disease Heart 96 2010 368 371
23. F. Catella-Lawson, M.P. Reilly, and S.C. Kapoor Cyclooxygenase inhibitors and the antiplatelet effects of aspirin N Engl J Med 345 2001 1809 1817
24. G. DiMinno, M.J. Silver, and A.M. Cerbone Trial of repeated low-dose aspirin in diabetic angiopathy Blood 68 1986 886 891
25. C. Perneby, N.H. Wallen, and C. Rooney Dose- and time-dependent antiplatelet effects of aspirin Thromb Haemost 95 2006 652 658
26. G. Di Minno, M.J. Silver, and S. Murphy Monitoring the entry of new platelets into the circulation after ingestion of aspirin Blood 61 1983 1081 1085
27. C. Patrono, L.A. Garcia Rodriguez, and R. Landolfi Low-dose aspirin for the prevention of atherothrombosis N Engl J Med 353 2005 2373 2383
28. E.H. Awtry, and J. Loscalzo Aspirin Circulation 101 2000 1206 1218
29. C. Patrono, and B. Rocca Drug insight: aspirin resistance - fact or fashion? Nat Clin Pract Cardiovasc Med 4 2007 42 50
30. A.S. Brown, Y. Hong, and A. de Belder Megakaryocyte ploidy and platelet changes in human diabetes and atherosclerosis Arterioscler Thromb Vasc Biol 17 1997 802 807
31. S. Pascale, G. Petrucci, and A. Dragani Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target Blood 2012
32. G. De Berardis, M. Sacco, and G.F. Strippoli Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials BMJ 339 2009 b4531
33. T. Geisler, K. Mueller, and S. Aichele Impact of inflammatory state and metabolic control on responsiveness to dual antiplatelet therapy in type 2 diabetics after PCI: prognostic relevance of residual platelet aggregability in diabetics undergoing coronary interventions Clin Res Cardiol 99 2010 743 752
34. M. Lordkipanidze, C. Pharand, and E. Schampaert A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease Eur Heart J 28 2007 1702 1708
35. S. Kaptoge, E. Di Angelantonio, and G. Lowe C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis Lancet 375 2010 132 140
36. K.K. Koh, S.H. Han, and M.J. Quon Inflammatory markers and the metabolic syndrome: insights from therapeutic interventions J Am Coll Cardiol 46 2005 1978 1985
37. A.R. Lucas, R. Korol, and C.J. Pepine Inflammation in atherosclerosis: some thoughts about acute coronary syndromes Circulation 113 2006 e728 e732
38. T. Geisler, N. Anders, and M. Paterok Platelet response to clopidogrel is attenuated in diabetic patients undergoing coronary stent implantation Diabetes Care 30 2007 372 374
39. E.L. Grove, A.M. Hvas, and H.L. Johnsen A comparison of platelet function tests and thromboxane metabolites to evaluate aspirin response in healthy individuals and patients with coronary artery disease Thromb Haemost 103 2010 1245 1253